Clinical trials
Breast Carcinoma clinical trials
Below are recruiting breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 365 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT04985032Recruiting
Radiation after lumpectomy for selected breast tumors
This trial tests a shorter, focused type of radiation (APBI using SBRT) after lumpectomy for certain early breast cancers. It may help by targeting only the part of the breast where the tumor was, rather than treating the whole breast, while keeping safety and cancer control in mind.
Stuart, FloridaAges 50–100 - NCT07339306Recruiting
Fluorescent needle test for breast duct micro-lesions
This trial tests a new glowing needle that helps doctors find and sample tiny abnormal areas in breast ducts during surgery. It aims to make the procedure more precise.
Shenyang, LiaoningAges 18–75 - NCT07047872Recruiting
3D-printed breast form study for women after mastectomy
This study tests a custom 3D-printed external breast form for people who had a mastectomy without reconstruction. It aims to see if it improves comfort and satisfaction.
Rochester, MinnesotaAges 18 years+ - NCT06028022RecruitingPhase 2
Reishi mushroom for fatigue and joint/muscle pain in breast cancer
This trial tests whether a reishi mushroom extract can help reduce fatigue and joint or muscle pain in people with breast cancer who are taking aromatase inhibitors. If you have these symptoms, you may be able to join.
Albert Lea, MinnesotaAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT07206121Recruiting
Study of a new device for breast cancer surgery
This trial tests a device that uses radiofrequency energy to help remove breast cancer during surgery. It may be an option for women over 50 with a specific type of early-stage breast cancer.
Galveston, TexasAges 50 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT07764796Recruiting
Mobile health support for breast cancer screening in Kenya
This study tests a mobile health program that helps women in Nairobi, Kenya get screened for breast cancer earlier. It aims to guide women through the screening process and connect them with the right care.
Atlanta, GeorgiaAges 18 years+ - NCT06475937RecruitingPhase 1
DM001 for advanced solid tumors study
This study tests an experimental drug called DM001 for people with certain advanced cancers (breast, lung, stomach, gastroesophageal, or colorectal) that have not responded to or are not helped by standard treatments. The goal is to see if the drug is safe and how it affects the tumors.
Nashville, TennesseeAges 18 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT07644702Recruiting
Community health forums to increase breast cancer screening
This study invites rural and low-income women to join free community forums that teach about breast cancer screening and clinical trials. The goal is to help more women get mammograms (breast X-rays) and learn about research opportunities that might benefit their health.
Eau Claire, WisconsinAges 50–74 - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06261918Recruiting
Breast cancer study: linking metabolism to tumor behavior
This study looks at how your metabolism (things like blood sugar and cholesterol) might be linked to tumor genes and growth in people with breast cancer. The goal is to find new ways to treat the disease based on your metabolic profile. You may be eligible if you have locally advanced breast cancer (Stage II–III) and are willing to share your medical records.
RomaAges 18 years+ - NCT07080944Recruiting
Lymph node biopsy after chemo for inflammatory breast cancer
This trial is testing if a less invasive sentinel lymph node biopsy can replace more extensive lymph node removal in women with inflammatory breast cancer who have had chemotherapy and whose nodes appear cancer-free. This could help avoid unnecessary side effects.
MilanAges 18 years+ - NCT06708910Recruiting
Using AI and PET/MRI to predict breast cancer response
This trial uses a special PET/MRI scan combined with artificial intelligence to see if it can predict whether HER2-positive breast cancer will completely disappear after treatment given before surgery. The goal is to learn who might avoid surgery or get a more tailored approach.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06557057Recruiting
Aromatase inhibitors and diabetes risk in breast cancer
This study looks at how aromatase inhibitors, a type of hormone therapy for breast cancer, affect blood sugar and diabetes risk. It compares women taking these drugs to those on tamoxifen or healthy women, to see if there are changes in glucose control.
Rochester, MinnesotaAges Any age - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT03408353Recruiting
MERIT study uses mammogram and blood tests to assess breast cancer risk
This study looks for signs in blood samples and imaging that may help estimate breast cancer risk earlier. You would do a mammogram and give blood at the start and then again at yearly follow-up visits.
Houston, TexasAges 25–80 - NCT04902937Recruiting
Testing how added radiation may work by immune and tumor markers
This study looks at people with non-metastatic invasive breast cancer who are getting curative breast surgery followed by planned radiation (sometimes with other anti-cancer medicines). Researchers want to understand whether a patient’s age and certain immune/tumor blood features can predict how well radiation helps.
JenaAges 18 years+ - NCT05056818Recruiting
Compare two types of breast X-ray images for reading accuracy
This study compares a computer-generated (“synthetic”) mammogram to the standard full-field digital mammogram to see which gives better image-reading results. It may help improve how breast images are interpreted in everyday practice.
Houston, TexasAges 18 years+
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast carcinoma?
- Yes. Clin2 currently lists 365 recruiting breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.